Tofacitinib Inhibits STAT Phosphorylation and Matrix Metalloproteinase-3, -9 and -13 Production by C28/I2 Human Juvenile Chondrocytes
Jessica R Thorpe,Rachel A Wilson,Sam Mesiano,Charles J Malemud
DOI: https://doi.org/10.2147/OARRR.S363736
2022-10-05
Open Access Rheumatology: Research and Reviews
Abstract:Jessica R Thorpe, 1 Rachel A Wilson, 2 Sam Mesiano, 2 Charles J Malemud 1 1 Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA; 2 Department of Reproductive Biology, Case Western Reserve University School of Medicine, University Hospitals Cleveland, Cleveland, OH, 44106, USA Correspondence: Charles J Malemud, Department of Medicine, Division of Rheumatic Diseases, Foley Medical Building, 2061 Cornell Road, Room 207, Cleveland, OH, 44106-5076, USA, Tel +1 216 844-7846 ; +1 216 536-1945, Fax +1 216 844-2288, Email ; Purpose: This in vitro study was designed to determine the effect of the pan-Janus kinase inhibitor, Tofacitinib, on basal and interleukin-6 (IL-6)-induced signal transducers and activators of transcription (STAT) phosphorylation and matrix metalloproteinase (MMP) gene expression and MMP production by C28/I2 human chondrocytes. Methods: C28/I2 chondrocytes were grown to a confluent high-density and treated either with recombinant human IL-6 (rhIL-6; 10– 20ng/mL) or maintained in the basal state for up to 60 min. MMP gene expression was determined using RT-PCR and MMP production by semi-quantitative immunohistochemistry. The effect of IL-6 with or without Tofacitinib on activation of STAT proteins was determined from quantitative Western blots. Results: C28/I2 chondrocytes produced STAT1, STAT3 and STAT5AB which were phosphorylated (p) following treatment with rhIL-6 for 30 min. Tofacitinib (2.5nM– 100nM) decreased rhIL-6-induced activation of STAT1, STAT3, and STAT5AB as well as decreasing the expression of MMP3 and MMP13 but not MMP9, MMP1 or MMP2 . In addition, Tofacitinib (50nM) reduced the number of rhIL-6-induced MMP3-, and MMP13- antibody-positive C28/I2 chondrocytes. However, Tofacitinib did decrease the number of MMP9-antibody-positive C28/I2 chondrocytes. Conclusion: Taken together, these data showed that Tofacitinib, a pan-JAK small molecule inhibitor employed for the medical therapy of rheumatoid arthritis was a potent inhibitor of rhIL-6-induced STAT phosphorylation that appeared to be coupled to the inhibition of MMP-3, -9 and -13 production by C28/I2 chondrocytes. Keywords: arthritis, cytokines, Janus kinase, signal transducers and activators of transcription Matrix metalloproteinases (MMPs) play a crucial role in the pathogenesis and progression of rheumatoid arthritis (RA). 1 At the cellular level, RA is characterized by the migration of immune and non-immune cells from the peripheral circulation to the synovium and synovial joint fluid where activated synovial fibroblasts, T-cells, B-cells, dendritic cells, macrophages and neutrophils 2,3 contribute to an elevated level of pro-inflammatory cytokines, several of which [eg interleukin-1β (IL-1β), IL-6, IL-17, tumor necrosis factor-α (TNF-α)] are intimately involved in upregulating matrix metalloproteinase (MMP) gene expression. In effect, the upregulation of MMP gene expression occurs mainly through the capacity of these pro-inflammatory cytokines to activate the stress-activated/mitogen-activated protein kinase (SAPK/MAPK) and/or the Janus Kinase/Signal Transducers and Activators of Transcription (JAK-STAT) signaling pathways by activated immune cells, synovial tissue fibroblasts and articular chondrocytes. 4–6 In RA, the biological activity of the MMP family is principally involved in the degradation of cartilage extracellular matrix (ECM) proteins, typically, Type II collagen, the sulfated proteoglycan, aggrecan, the "minor" proteoglycans, including decorin, and biglycan, all of which are synthesized by chondrocytes. 7 These ECM proteins provide the biochemical/biomechanical mechanism crucial for the maintenance of cartilage homeostasis and therefore, synovial joint integrity. 7 As such, their loss from articular cartilage results in cartilage degradation in RA, as well as in osteoarthritis (OA) pathology. The MMP messenger RNAs (mRNAs) produced by cells involved in the RA process are translated and produced as latent pro-enzymes. The pro-MMPs must be activated to be fully functional and MMPs have been implicated in this process as well. 8 In addition, in RA a faulty endogenous MMP inhibitor system has been reported. Thus, under homeostatic conditions the biological activity of MMPs are regulated by a protein family referred to as tissue inhibitors of metalloproteinases (TIMPs). 8 Importantly, the pro-MMPs that were previously shown to be produced by chondrocytes in vitro in response to stimulation by various pro-inflammatory cytokines, were pro-MMP-1 (collagenase-1), pro-MMP-2 (72kDa gelati -Abstract Truncated-